The protein-based vaccine, which is about 90 per cent effective at preventing symptomatic coronavirus, received emergency-use approval from the Drugs Controller General of India
With Novovax’s vaccine, India will now have four vaccines for adolescents aged 12 years and older in India after Biological E’s Corbevax, Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin. AFP
India’s battle against coronavirus received a boost on Wednesday morning after the Drugs Controller General of India (DCGI) granted emergency-use authorisation to United States pharma giant Novavax for its vaccine for children aged 12 to 17 years.
As per an official statement released by Novovax, the vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by the Serum Institute of India (SII) under the brand name Covovax and is the first protein-based vaccine authorised for use in this age group in India.